NYMOX PHARMACEUTICAL CORP
NYMXF · OTCMCIK 1018735fmd_0YFJA6FKYS5TZS6H3PZK18Z0BNManufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard
Coverage: Jan 01, 2015 to Dec 31, 2025, 33 periods
Latest annual · FY2023
Millions- Total revenues
- 0
- Gross profit
- 0
- Operating income
- (4)
- Net income
- (4)
- Free cash flow
- (3)
Latest quarter · Q3 FY2024
Millions- Total revenues
- 0
- Gross profit
- 0
- Net income
- (1)
- Free cash flow
- (1)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2020 to FY2023
- n/m
- Net income, 5 yearsFY2019 to FY2024
- n/m
NYMOX PHARMACEUTICAL CORP (NYMXF) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Operating income | -$4.3 million | -$8.4 million | 20-F 2025-06-03 · proof | |
| Net income | -$4.5 million | -$8.8 million | 20-F 2025-06-03 · proof | |
| Cash from operating activities | -$2.6 million | -$4.1 million | 20-F 2025-06-03 · proof | |
| Free cash flow | -$2.6 million | -$4.1 million | 20-F 2025-06-03 · proof | |
| Total assets | $654,000 | $627,000 | +4.3% | 20-F 2025-06-03 · proof |
| Total liabilities | $7.4 million | $3.8 million | +95.5% | 20-F 2025-06-03 · proof |
- What was NYMOX PHARMACEUTICAL CORP (NYMXF)'s operating income in fiscal 2024?
- NYMOX PHARMACEUTICAL CORP (NYMXF) reported operating income of -$4.3 million for fiscal 2024 (the year ended Dec 31, 2024), against -$8.4 million the year before. Source: the 20-F filed with the SEC on Jun 3, 2025. SEC
- What was NYMOX PHARMACEUTICAL CORP (NYMXF)'s net income in fiscal 2024?
- NYMOX PHARMACEUTICAL CORP (NYMXF) reported net income of -$4.5 million for fiscal 2024 (the year ended Dec 31, 2024), against -$8.8 million the year before. Source: the 20-F filed with the SEC on Jun 3, 2025. SEC
- What was NYMOX PHARMACEUTICAL CORP (NYMXF)'s cash from operating activities in fiscal 2024?
- NYMOX PHARMACEUTICAL CORP (NYMXF) reported cash from operating activities of -$2.6 million for fiscal 2024 (the year ended Dec 31, 2024), against -$4.1 million the year before. Source: the 20-F filed with the SEC on Jun 3, 2025. SEC
- What was NYMOX PHARMACEUTICAL CORP (NYMXF)'s free cash flow in fiscal 2024?
- NYMOX PHARMACEUTICAL CORP (NYMXF) reported free cash flow of -$2.6 million for fiscal 2024 (the year ended Dec 31, 2024), against -$4.1 million the year before. Source: the 20-F filed with the SEC on Jun 3, 2025. SEC
- What are NYMOX PHARMACEUTICAL CORP (NYMXF)'s total assets?
- As of Dec 31, 2024, NYMOX PHARMACEUTICAL CORP (NYMXF) reported total assets of $654,000, against $627,000 a year earlier (+4.3%). Source: the 20-F filed with the SEC on Jun 3, 2025. SEC
- What are NYMOX PHARMACEUTICAL CORP (NYMXF)'s total liabilities?
- As of Dec 31, 2024, NYMOX PHARMACEUTICAL CORP (NYMXF) reported total liabilities of $7.4 million, against $3.8 million a year earlier (+95.5%). Source: the 20-F filed with the SEC on Jun 3, 2025. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:NYMXF&period_type=annual&limit=5"Information only, not investment advice.